Evaluating real-world diagnostic and treatment patterns, risk of thromboembolic events, and mortality for polycythemia vera across an integrated academic-community cancer network
Retrospective analysis reveals higher thromboembolic events in older patients with polycythemia vera, indicating treatment disparities in the integrated cancer network.
Key Points
Thromboembolic events were significantly higher in patients treated at community sites, reaching 27.6% compared to 10.6% at the Comprehensive Cancer Center.
Overall survival was similar across treatment sites, with a median of 136.4 months for all polycythemia vera patients analyzed.
Diagnostic testing was less frequently performed at community sites, with 31.5% undergoing next-generation sequencing versus 61.8% at the Comprehensive Cancer Center.
Higher-risk polycythemia vera patients were less likely to receive effective cytoreductive therapy beyond initial treatment in community practices.